{{Rsnum
|rsid=1867898
|Chromosome=2
|position=133762000
|Orientation=plus
|GMAF=0.2489
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 3.1 | 15.4 | 81.5
| HCB | 11.1 | 48.9 | 40.0
| JPT | 9.1 | 56.8 | 34.1
| YRI | 7.9 | 50.8 | 41.3
| ASW | 0.0 | 0.0 | 0.0
| CHB | 11.1 | 48.9 | 40.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=20560679
|Title=Response to Methadone Maintenance Treatment is Associated with the MYOCD and GRM6 Genes
}}{{PMID|18195715|OA=1
}} Genotype patterns that contribute to increased risk for or protection from developing heroin addiction.

{{PMID|18725235|OA=1
}} Bidirectional translational research: Progress in understanding addictive diseases.

{{PMID|19155191|OA=1
}} Opiate and cocaine addiction: from bench to clinic and back to the bench.